Juvenile Idiopathic Arthritis
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.
The study will last about 44 weeks and may include up to 17 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active
- Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)
- Participants must not have systemic JIA, with or without active systemic features
- Participants must not have persistent oligoarticular arthritis
- Participants must not have been previously treated with a Janus kinase (JAK) inhibitor